Ameloblastoma of the jaw: Treatment with radiation therapy and a case report

C. T. Miyamoto, L. W. Brady, Arnold Markoe, D. Salinger

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Ameloblastoma of the jaw is an aggressive benign tumor of epithelial origin that has generally been treated surgically even for metastases. This article is a review of the literature and a report of a previously unpublished case. Despite earlier reports, it is suggested that the available data clearly indicate that it is a radiosensitive tumor. In this report, specific recommendations for radiation therapy are outlined, and guidelines for treatment planning, radiation dosage, and fractionation, expected outcome and follow-up are given.

Original languageEnglish
Pages (from-to)225-230
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume14
Issue number3
StatePublished - Jan 1 1991
Externally publishedYes

Fingerprint

Ameloblastoma
Jaw
Radiotherapy
Radiation Dosage
Neoplasms
Guidelines
Neoplasm Metastasis
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ameloblastoma of the jaw : Treatment with radiation therapy and a case report. / Miyamoto, C. T.; Brady, L. W.; Markoe, Arnold; Salinger, D.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 14, No. 3, 01.01.1991, p. 225-230.

Research output: Contribution to journalArticle

@article{bf0b7515ede1491f83cced52ef8d749a,
title = "Ameloblastoma of the jaw: Treatment with radiation therapy and a case report",
abstract = "Ameloblastoma of the jaw is an aggressive benign tumor of epithelial origin that has generally been treated surgically even for metastases. This article is a review of the literature and a report of a previously unpublished case. Despite earlier reports, it is suggested that the available data clearly indicate that it is a radiosensitive tumor. In this report, specific recommendations for radiation therapy are outlined, and guidelines for treatment planning, radiation dosage, and fractionation, expected outcome and follow-up are given.",
author = "Miyamoto, {C. T.} and Brady, {L. W.} and Arnold Markoe and D. Salinger",
year = "1991",
month = "1",
day = "1",
language = "English",
volume = "14",
pages = "225--230",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Ameloblastoma of the jaw

T2 - Treatment with radiation therapy and a case report

AU - Miyamoto, C. T.

AU - Brady, L. W.

AU - Markoe, Arnold

AU - Salinger, D.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Ameloblastoma of the jaw is an aggressive benign tumor of epithelial origin that has generally been treated surgically even for metastases. This article is a review of the literature and a report of a previously unpublished case. Despite earlier reports, it is suggested that the available data clearly indicate that it is a radiosensitive tumor. In this report, specific recommendations for radiation therapy are outlined, and guidelines for treatment planning, radiation dosage, and fractionation, expected outcome and follow-up are given.

AB - Ameloblastoma of the jaw is an aggressive benign tumor of epithelial origin that has generally been treated surgically even for metastases. This article is a review of the literature and a report of a previously unpublished case. Despite earlier reports, it is suggested that the available data clearly indicate that it is a radiosensitive tumor. In this report, specific recommendations for radiation therapy are outlined, and guidelines for treatment planning, radiation dosage, and fractionation, expected outcome and follow-up are given.

UR - http://www.scopus.com/inward/record.url?scp=0025868328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025868328&partnerID=8YFLogxK

M3 - Article

C2 - 2031509

AN - SCOPUS:0025868328

VL - 14

SP - 225

EP - 230

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 3

ER -